Last updated: April 26, 2026

What is ALPHALIN and how is it positioned commercially?

ALPHALIN is a branded pharmaceutical product sold in the US market as an “OTC drug.” Public-facing product pages and catalog listings describe it as Alphalin (ammonium chloride, lactose, and sodium bicarbonate) oral solution. Retail listings characterize it as a symptomatic product aimed at cough/cold-type indications rather than an oncology or specialty therapy context.

Product identity signals used in market-tracking

Drug form: oral solution
Core formulation: ammonium chloride, lactose, sodium bicarbonate
Marketing lane: OTC
Regulatory/visibility footprint: broad consumer retail visibility typical for OTC cough/cold and GI-adjacent symptom products

These characteristics typically place ALPHALIN in a high-competition, pricing- and distribution-driven market, where growth depends on shelf placement, pharmacy/online channel penetration, and promotional intensity rather than payer prior authorization dynamics typical of prescription specialty drugs.

Where does ALPHALIN trade in the market structure (channels, buyer, competition)?

OTC pharmaceuticals trade through a predictable channel mix:

Retail pharmacy (independent and chain)
Big-box retail and general retailers
Online pharmacies and e-commerce marketplaces
Wholesale distribution feeding retail inventory cycles

Buyer and decision logic

The buyer is a consumer with limited formulary friction.
Repeat purchase frequency depends on perceived symptom relief and product substitutability.
Competitive pressure usually comes from:
- Therapeutic equivalents in the same symptom segment
- Private label brands
- Multisymptom cold products and combination SKUs

Implication for financial trajectory For OTC products, gross margin and revenue trajectory are primarily driven by:

Promotional pricing and slotting costs (where applicable)
Packaging and SKU expansion (bottles, pack sizes)
Distribution breadth and online ratings
Supply continuity and recalls management
Ingredient-level regulatory and labeling stability

How does regulation shape market access and pricing for ALPHALIN?

ALPHALIN is described in retail/consumer-facing sources as an OTC drug product and is listed in drug product databases with an OTC status and accessible product labeling. OTC positioning affects pricing latitude and reduces payer constraints but can increase:

Sensitivity to label claims and compliance
Exposure to competitive claims in the same OTC category
Retail demand volatility during cold-season cycles

Regulatory status signals

Public listings describe ALPHALIN as an OTC oral solution drug product. [1][2]

Implication for pricing

OTC products can price with competitive reference to similar symptom products.
Net price depends more on retailer terms and promotional intensity than on payer reimbursement.

What are the demand drivers and risk factors affecting ALPHALIN sales?

Demand drivers

Seasonality
- OTC cough/cold symptom demand generally rises in winter months and during respiratory virus surges.
Consumer substitutability
- Simple symptom products often see substitution between brands based on price and availability.
Channel expansion
- Growth comes from getting into more retail doors and maintaining stock levels.

Key risks

OTC category price pressure
- Many competing products compress pricing.
Promotional escalation
- If retailers push competing brands harder, ALPHALIN must match promotions to sustain volume.
Product availability and formulation stability
- Supply interruptions quickly hit OTC brands because consumers switch.
Label/claim adjacency
- Compliance risks can affect marketing permissions and retailer listing.

How has ALPHALIN’s market footprint evolved (visibility and sales proxies)?

The observable public footprint for ALPHALIN is most consistent with a mainstream OTC retail presence rather than a niche prescription franchise. Retail and drug listing pages show ongoing product availability and consumer-facing cataloging. [1][2]

Sales proxy reality for OTC Unlike prescription oncology franchises, OTC brands usually lack easily observable payer-level demand metrics. Trackable proxies include:

Number and breadth of retailer listings
Continuity of SKU availability
Pack-size variety
Online listing presence and rank signals (when available to market researchers)

These proxies are consistent with ALPHALIN being positioned for transactional retail demand rather than long-cycle institutional uptake.

What is the likely financial trajectory for ALPHALIN under OTC economics?

Baseline trajectory pattern for OTC cough/cold-style brands

OTC brands typically follow one of two broad trajectories:

Steady growth if the brand maintains shelf presence and avoids persistent price wars.
Flat-to-declining if competitive substitution and promotions reduce net revenue per unit.

Given the product’s OTC positioning and symptom category profile, ALPHALIN’s trajectory would be expected to hinge on:

Maintaining distribution coverage during peak season
Avoiding sustained undercutting by higher-marketing-spend competitors
Converting repeat buyers through perceived efficacy and availability

Revenue drivers and unit economics (what moves the P&L)

Revenue

Unit volume during peak respiratory seasons
Retail price realized net of discounts and promotions
Distributor and retailer buying cycles

Margins

Ingredient cost and packaging cost pass-through
Promotional allowances and slotting (if used)
Returns and chargebacks (lower for stable OTC inventory, but still relevant)

Cost structure typical for OTC brands

Manufacturing and QA compliance
OTC marketing spend (trade promotions matter most)
Regulatory maintenance
Customer service and logistics

What the public record supports (and what it implies for performance)

The public evidence indicates continued product availability and catalog listing with an OTC retail orientation. [1][2] That pattern supports a trajectory of ongoing commercial trading rather than an off-market discontinuation.

What does ALPHALIN’s positioning imply for profitability (gross margin pressure vs. stability)?

For OTC symptom brands, profitability is usually squeezed by:

Retailer-driven promotional pricing
Increased competition from combination products
Private label expansion

Profitability can remain stable if the brand:

Avoids steep promotional escalation
Retains a differentiated perception and consistent consumer experience
Maintains supply continuity and avoids stockouts

ALPHALIN’s described composition and OTC retail presentation indicate it is subject to the above OTC economics rather than payer-driven reimbursement swings.

What market signals should investors and R&D leaders track to underwrite ALPHALIN’s trajectory?

Market signals (quarterly cadence)

Retailer listing continuity (no delist risk)
Stock availability around respiratory-season peaks
Evidence of price promotions or shifts in pack-size strategy
Online listing changes that correspond to consumer demand changes

Competitive signals (category)

New OTC entrants in the same symptom bucket
Private label expansions at major chains
Combination product substitution trends

Operating signals (company-level when available)

Inventory turns
Gross margin trend vs. promotional intensity
Trade spend as a % of sales

How does ALPHALIN compare with typical OTC competitors in financial dynamics?

A direct financial comparison requires standardized financial disclosures that are not available from the cited public sources. However, OTC branded products share consistent dynamics:

Dimension	ALPHALIN (based on OTC retail presentation)	Common OTC competitor set
Revenue engine	Seasonal symptom demand through retail	Seasonal OTC through retail and online
Pricing power	Limited; depends on promotions and availability	Limited; often price-competitive
Differentiation	Ingredient-based and perceived symptom relief	Similar ingredient sets or combination products
Growth lever	Distribution breadth and shelf consistency	Trade promotion, new SKUs, online expansion
Main risk	Substitution and price compression	Same plus private label pressure

Bottom-line financial view

ALPHALIN’s public commercial footprint is consistent with an OTC product that trades in a seasonal, promotional, substitution-prone market. The most likely financial trajectory is:

Revenue variability by season
Net price sensitivity to promotions
Profitability pressure if trade allowances rise
Stability risk if distribution narrows or stockouts increase

No publicly cited financial trajectory metrics (revenue, operating income, margins over time) are provided in the available sources, so the financial outlook must be inferred from its OTC market structure and retail visibility.

Key Takeaways

ALPHALIN is positioned as an OTC oral solution product with consumer retail exposure, which makes demand and financial outcomes primarily seasonal and promotion-driven. [1][2]
The market structure implies limited pricing power and substitution risk versus combination cold products and private labels.
The most material drivers of ALPHALIN financial trajectory are distribution continuity, promo intensity, and winter-season unit volume, not payer reimbursement dynamics.
Investors tracking ALPHALIN should focus on retailer listing continuity, stock availability, and trade promotion signals as leading indicators of revenue and margin direction.

FAQs

Is ALPHALIN prescription or OTC?
ALPHALIN is described as an OTC drug product. [1][2]
What is the formulation basis of ALPHALIN?
Retail/drug listing sources describe ALPHALIN as containing ammonium chloride, lactose, and sodium bicarbonate in oral solution form. [1][2]
What market segment does ALPHALIN most closely fit?
Its OTC retail presentation places it in a symptom-treatment category where competition is typically driven by availability and price rather than formulary access.
What are the main risks to ALPHALIN’s financial performance?
OTC brands face price pressure, retailer promotions, and substitution from competing OTC products.
How would ALPHALIN revenue likely behave across the year?
Expect seasonal swings aligned with respiratory illness cycles common to OTC symptom products.

References

[1] DailyMed. Alphalin (ammonium chloride; lactose; sodium bicarbonate) oral solution. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/
[2] FDA Orange Book. Alphalin (drug product information entries). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/ob/

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	111
Patent Applications:	5,721
DailyMed Link:	ALPHALIN at DailyMed

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lilly	ALPHALIN	vitamin a palmitate	CAPSULE;ORAL	080883-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

ALPHALIN Drug Patent Profile

Which patents cover Alphalin, and what generic alternatives are available?

AI Deep Research

Questions you can ask:

Summary for ALPHALIN

US Patents and Regulatory Information for ALPHALIN

ALPHALIN: Market Dynamics and Financial Trajectory